6-O-BENZYLGUANINE

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII 01KC87F8FE
EPA CompTox DTXSID20173700

Structure

InChI Key KRWMERLEINMZFT-UHFFFAOYSA-N
Smiles Nc1nc(OCc2ccccc2)c2nc[nH]c2n1
InChI
InChI=1S/C12H11N5O/c13-12-16-10-9(14-7-15-10)11(17-12)18-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H3,13,14,15,16,17)

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H11N5O
Molecular Weight 241.25
AlogP 1.51
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 89.71
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 18.0
Assay Description Organism Bioactivity Reference
Inhibition of AGT activity to 50% of control rate in HT-29 cell extract None 180.0 nM
concentration required to reduce AGT activity to 50% of control rate in intact HT-29 human colorectal carcinoma cells None 58.0 nM
In vitro inhibition of MGMT using cell free extracts from HeLa S3 cells Homo sapiens 620.0 nM
O6-Alkylguanine-DNA Alkyltransferase-Inactivating Activity (Concentration of inactivator required to produce 50% reduction in ATPase activity) None 40.0 nM
O6-Alkylguanine-DNA Alkyltransferase-Inactivating Activity in Raji cells (Concentration of inactivator required to produce 50% reduction in ATPase activity) None 100.0 nM
Inhibition of ASK1 assessed as phosphorylated fluorescent peptide at 10 uM by mobility shift assay None 30.0 %
Inhibition of human recombinant AGT assessed as prevention of O6-(2-chloroethyl)guanine and N1,O6-ethanoguanine-DNA adduct repair at 0.1 uM after 30 mins by fluorescence assay Homo sapiens 47.0 %
Inhibition of AGT in human HL60 cells assessed as AGT levels using [3H]AGT after 2 hrs Homo sapiens 39.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens -19.9 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 27.23 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 20.8 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 4.967 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.42 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.15 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.15 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.42 %

Cross References

Resources Reference
ChEMBL CHEMBL407874
DrugBank DB11919
FDA SRS 01KC87F8FE
PDB OBG
PubChem 4578
SureChEMBL SCHEMBL61740
ZINC ZINC000005425464
CONTENTS